PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33810533-5 2021 To assess the involvement of NF-kappaB signaling in basal inflammatory activation, CTEPH-ECs were incubated with the NF-kappaB inhibitor Bay 11-7085. BAY 11-7085 137-148 nuclear factor kappa B subunit 1 Homo sapiens 117-126 34357463-0 2021 Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFkappaB signaling axis. BAY 11-7085 43-53 nuclear factor kappa B subunit 1 Homo sapiens 129-137 34907738-5 2021 Inhibition of NF-kappaB using inhibitor Bay 11-7085 repressed proliferation, survival, migration, and invasion but increased apoptosis in 143B and MG63 OS cells, indicating that NF-kappaB is critically implicated in the oncogenesis of OS. BAY 11-7085 40-51 nuclear factor kappa B subunit 1 Homo sapiens 14-23 34907738-5 2021 Inhibition of NF-kappaB using inhibitor Bay 11-7085 repressed proliferation, survival, migration, and invasion but increased apoptosis in 143B and MG63 OS cells, indicating that NF-kappaB is critically implicated in the oncogenesis of OS. BAY 11-7085 40-51 nuclear factor kappa B subunit 1 Homo sapiens 178-187 34907738-6 2021 Notably, Bay 11-7085 not only inactivated NF-kappaB but also reduced the phosphorylation of AKT via its induction of PTEN, suggesting the existence of a novel NF-kappaB/PTEN/PI3K/AKT axis. BAY 11-7085 9-20 nuclear factor kappa B subunit 1 Homo sapiens 42-51 34907738-6 2021 Notably, Bay 11-7085 not only inactivated NF-kappaB but also reduced the phosphorylation of AKT via its induction of PTEN, suggesting the existence of a novel NF-kappaB/PTEN/PI3K/AKT axis. BAY 11-7085 9-20 nuclear factor kappa B subunit 1 Homo sapiens 159-168 34907738-7 2021 In vivo, Bay 11-7085 suppressed tumor growth in the bone by targeting NF-kappaB and AKT. BAY 11-7085 9-20 nuclear factor kappa B subunit 1 Homo sapiens 70-79 34298122-8 2021 Notably, the BAY 11-7085, a NF-kappaB signaling selective inhibitor, was shown to efficiently suppressed downregulation of DAPK2-induced oncogenic phenotypes of NSCLC cells. BAY 11-7085 13-24 nuclear factor kappa B subunit 1 Homo sapiens 28-37 34621174-9 2021 BPA exerted its effects on RACK1 via NF-kappaB, as shown using the NF-kappaB inhibitor BAY11-7085 and NF-kappaB-specific luciferase reporter assay. BAY 11-7085 87-97 nuclear factor kappa B subunit 1 Homo sapiens 67-76 34357463-12 2021 Gefitinib and Bay 11-7085 combination treatment was found to be useful in chemosensitizing the Gefitinib-resistant OSCC cells by capitulating the EGFR- NFkappaB signaling axis. BAY 11-7085 14-25 nuclear factor kappa B subunit 1 Homo sapiens 152-160 32835592-10 2020 The IL-1beta-mediated upregulation of occludin was prevented by the NF-kappaB inhibitor BAY 11-7085. BAY 11-7085 88-99 nuclear factor kappa B subunit 1 Homo sapiens 68-77 33760166-12 2021 In addition, treatment with BAY11-7085 (NF-kappaB activator) was demonstrated to reverse the inhibitory effects of miR-101-3p expression on both IL-10 and IFN-gamma in SLE PBMCs. BAY 11-7085 28-38 nuclear factor kappa B subunit 1 Homo sapiens 40-49 34116085-10 2021 In addition, Bay11-7085 treatment causes attenuation of the relative levels of OTA-mediated ERK1/2 phosphorylation, suggesting a cross-talk between NF-kappaB and the MAPK/ERK pathway. BAY 11-7085 13-23 nuclear factor kappa B subunit 1 Homo sapiens 148-157 32001619-9 2020 Consistent with this, the IKK inhibitor BAY11-7085 and dominant-negative mutant IkappaBalphaM inhibited NFkappaB activity and increased P-P53, P53, and P21/WAF1/CIP1 levels in a ROS-dependent manner. BAY 11-7085 40-50 nuclear factor kappa B subunit 1 Homo sapiens 104-112 32207045-7 2020 RESULTS: Inhibition of NF-kappaB signals using Bay11-7085 increased miR-124 expression whereas exposure to TNF-alpha decreased it. BAY 11-7085 47-57 nuclear factor kappa B subunit 1 Homo sapiens 23-32 29291542-3 2018 Protocatechuic acid, Akt inhibitor, Bay 11-7085 and N-acetylcysteine reduced the lipopolysaccharide-caused production of cytokines and chemokines, expression of cyclooxygenase, increase in the levels and activities of Toll-like receptor-4, p-Akt and mTOR, activation of NF-kappaB, phosphorylation of the JNK and p38-MAPK, and production of reactive oxygen species in keratinocytes. BAY 11-7085 36-47 nuclear factor kappa B subunit 1 Homo sapiens 270-279 31042008-6 2019 miR-21-5p and cytokine expression were downregulated by BAY11-7085 and caffeic acid phenylethyl ester (CAPE), specific and potent NF-kappaB inhibitors. BAY 11-7085 56-66 nuclear factor kappa B subunit 1 Homo sapiens 130-139 30940449-6 2019 Moreover, NF-kappaB pathway is activated in MCF-7/adr cells, however, treatment with Bay 11-7085, one specific inhibitor of this pathway, reverses resistance to doxorubicin, suggesting that NF-kappaB pathway activation contributes to doxorubicin resistance in MCF-7/adr cells. BAY 11-7085 85-96 nuclear factor kappa B subunit 1 Homo sapiens 10-19 30940449-6 2019 Moreover, NF-kappaB pathway is activated in MCF-7/adr cells, however, treatment with Bay 11-7085, one specific inhibitor of this pathway, reverses resistance to doxorubicin, suggesting that NF-kappaB pathway activation contributes to doxorubicin resistance in MCF-7/adr cells. BAY 11-7085 85-96 nuclear factor kappa B subunit 1 Homo sapiens 190-199 31092435-8 2019 Treatment with a NF-kappaB inhibitor (BAY 11-7085) was able to reverse PFOA-induced cell invasiveness. BAY 11-7085 38-49 nuclear factor kappa B subunit 1 Homo sapiens 17-26 29629844-9 2018 By using NF-kappaB inhibitor (BAY-11-7085) and VCAM-1 siRNA, we showed that VCAM-1 expression is downstream of NF-kappaB activation, and this NF-kappaB/VCAM-1 signaling pathway controls cord formation, adhesion, and the migration abilities of the HMVEC-dLy cells. BAY 11-7085 30-41 nuclear factor kappa B subunit 1 Homo sapiens 9-18 29629844-9 2018 By using NF-kappaB inhibitor (BAY-11-7085) and VCAM-1 siRNA, we showed that VCAM-1 expression is downstream of NF-kappaB activation, and this NF-kappaB/VCAM-1 signaling pathway controls cord formation, adhesion, and the migration abilities of the HMVEC-dLy cells. BAY 11-7085 30-41 nuclear factor kappa B subunit 1 Homo sapiens 111-120 29629844-9 2018 By using NF-kappaB inhibitor (BAY-11-7085) and VCAM-1 siRNA, we showed that VCAM-1 expression is downstream of NF-kappaB activation, and this NF-kappaB/VCAM-1 signaling pathway controls cord formation, adhesion, and the migration abilities of the HMVEC-dLy cells. BAY 11-7085 30-41 nuclear factor kappa B subunit 1 Homo sapiens 111-120 27259382-9 2016 To determine the mechanism behind the poor sensitivity of BMDCs to chemotherapy, we blocked the activity of the heterodimer protein NF-kappaB using the pharmacological inhibitor Bay 11-7085 and through the transfection of an adenovirus negative mutant of I kappa B alpha. BAY 11-7085 178-189 nuclear factor kappa B subunit 1 Homo sapiens 132-141 28710022-4 2017 Taxifolin, N-acetylcysteine, trolox, Akt inhibitor and Bay11-7085 attenuated the cholesterol oxidation product-induced changes in the apoptosis-related protein levels, activation of the Akt and NF-kappaB, reactive oxygen species production, GSH depletion and cell death. BAY 11-7085 55-65 nuclear factor kappa B subunit 1 Homo sapiens 194-203 27775688-3 2016 Modulation of NF-kappaB activity was accomplished through the specific NF-kappaB inhibitor (BAY 11-7085), triptolide, and Minnelide treatment, as well as overexpression of IKBalpha repressor and IKK activator plasmids. BAY 11-7085 92-103 nuclear factor kappa B subunit 1 Homo sapiens 14-23 27221774-5 2016 Myricetin, Akt inhibitor, Bay 11-7085 (an inhibitor of NF-kappaB activation), rapamycin (mTOR inhibitor) and N-acetylcysteine attenuated TNF-alpha-induced activation of Akt, mTOR and NF-kappaB. BAY 11-7085 26-37 nuclear factor kappa B subunit 1 Homo sapiens 55-64 22313677-5 2012 MEP-induced VCAM-1 and ICAM-1 protein expression was inhibited by NF-kappaB inhibitor BAY 11-7085. BAY 11-7085 86-97 nuclear factor kappa B subunit 1 Homo sapiens 66-75 25760020-10 2015 By contrast, NF-kappaB-p65 subunit phosphorylation was inhibited in cells that had been treated with BAY-117085, an NF-kappaB pathway inhibitor. BAY 11-7085 101-111 nuclear factor kappa B subunit 1 Homo sapiens 13-22 25760020-10 2015 By contrast, NF-kappaB-p65 subunit phosphorylation was inhibited in cells that had been treated with BAY-117085, an NF-kappaB pathway inhibitor. BAY 11-7085 101-111 nuclear factor kappa B subunit 1 Homo sapiens 116-125 23175174-10 2013 BAY 117085 and curcumin, which are two NF-kappaB inhibitors, led to a decrease in the ratio of ADAMTS9/beta-actin. BAY 11-7085 0-10 nuclear factor kappa B subunit 1 Homo sapiens 39-48 22849349-5 2012 Furthermore, inhibition of NF-kappaB (nuclear factor kappaB) by the pharmacological antagonist BAY 11-7085 or an IkappaB (inhibitor of NF-kappaB) SuperRepressor prevented cytoprotective gene induction. BAY 11-7085 95-106 nuclear factor kappa B subunit 1 Homo sapiens 27-36 22849349-5 2012 Furthermore, inhibition of NF-kappaB (nuclear factor kappaB) by the pharmacological antagonist BAY 11-7085 or an IkappaB (inhibitor of NF-kappaB) SuperRepressor prevented cytoprotective gene induction. BAY 11-7085 95-106 nuclear factor kappa B subunit 1 Homo sapiens 38-59 22849850-9 2012 The release of IL-8 was inhibited by the NF-kappaB inhibitor, caffeic acid phenethyl ester (CAPE), an inhibitor of nuclear factor kappa-B alpha (IkappaBalpha) inhibitor, BAY 11-7085, and an inhibitor of nuclear factor kappa-B kinase-2 (IKK-2) inhibitor, SC-514, but not by a c-Jun N-terminal kinase (JNK) inhibitory peptide, L-JNKi1. BAY 11-7085 170-181 nuclear factor kappa B subunit 1 Homo sapiens 41-50 24609059-9 2014 The inflammatory effects of mitochondrial damage appeared to be dependent on ROS production and NF-kappaB activation since the inflammatory response was counteracted by both N-acetylcysteine and mitoTEMPO and it was also reduced by BAY-117085. BAY 11-7085 232-242 nuclear factor kappa B subunit 1 Homo sapiens 96-105 24227758-8 2014 Elevation of inflammatory mediators was not observed, however, upon hormone withdrawal in cells treated with the NF-kappaB inhibitor BAY 11-7085. BAY 11-7085 133-144 nuclear factor kappa B subunit 1 Homo sapiens 113-122 25427631-8 2014 GS and the NF-kappaB inhibitor BAY11-7085 suppressed DCA-induced CDX2 and COX-2 expression in EAC cells. BAY 11-7085 31-41 nuclear factor kappa B subunit 1 Homo sapiens 11-20 21211536-9 2011 Similar results were obtained with Bay 11-7085, an inhibitor of NF-kappaB. BAY 11-7085 35-46 nuclear factor kappa B subunit 1 Homo sapiens 64-73 21704193-6 2011 Bay 11-7085 (an inhibitor of NF-kappaB activation) and Akt inhibitor attenuated the TNF-alpha-induced formation of inflammatory mediators. BAY 11-7085 0-11 nuclear factor kappa B subunit 1 Homo sapiens 29-38 21704193-7 2011 3,4,5-Tricaffeoylquinic acid, Bay 11-7085, Akt inhibitor and N-acetylcysteine inhibited the TNF-alpha-induced activation of NF-kappaB, activation of Akt, and formation of reactive oxygen and nitrogen species. BAY 11-7085 30-41 nuclear factor kappa B subunit 1 Homo sapiens 124-133 20932173-9 2011 TGF-beta1-induced MMP-2 activity is inhibited by Bay11-7082 and Bay11-7085 (NF-kappaB inhibitors). BAY 11-7085 64-74 nuclear factor kappa B subunit 1 Homo sapiens 76-85 21506127-7 2011 In vitro, Bay 11-7085 inhibited constitutively active NF-kappaB expression in a dose-dependent manner and inhibition of NF-kappaB also down-regulated expression of the downstream target gene products Bcl-2, Bcl-XL (BCL2L1), XIAP and Survivin, leading to apoptosis via activation of the mitochondrial apoptotic pathway. BAY 11-7085 10-21 nuclear factor kappa B subunit 1 Homo sapiens 54-63 21081469-7 2011 Knockdown of NF-kappaB by short interfering RNA (siRNA) or specific inhibitor (Bay-11-7085) markedly suppressed nicotine-induced cell proliferation and upregulation of miR-16 and miR-21. BAY 11-7085 79-90 nuclear factor kappa B subunit 1 Homo sapiens 13-22 20688878-7 2010 Site-directed mutagenesis of the NF-kappaB element in ADAM-12 promoter and inhibition of NF-kappaB activity by Bay-11-7085 and MG-132 significantly reduced TGF-beta1-mediated increase of ADAM-12 promoter-driven gene expression. BAY 11-7085 111-122 nuclear factor kappa B subunit 1 Homo sapiens 89-98 19464389-6 2009 Bay 11-7085 (an inhibitor of NF-kappaB activation) and anti-oxidant N-acetylcysteine attenuated the TNF-alpha-induced formation of inflammatory mediators and reactive species. BAY 11-7085 0-11 nuclear factor kappa B subunit 1 Homo sapiens 29-38 19464389-7 2009 Hirsutenone, dexamethasone, cyclosporin A and Bay 11-7085 inhibited the TNF-alpha-induced phosphorylation of inhibitory kappaB and the activation of nuclear factor (NF)-kappaB. BAY 11-7085 46-57 nuclear factor kappa B subunit 1 Homo sapiens 149-175 19326361-8 2009 The nuclear delivery was inhibited with BAY 11-7085, an inhibitor of NF kappaB activation. BAY 11-7085 40-51 nuclear factor kappa B subunit 1 Homo sapiens 69-78 19317852-4 2009 The up-regulation of the P2Y(2)R was abrogated by pre-incubation with Bay 11-7085, an IkappaB-alpha phosphorylation inhibitor, which suggests that P2Y(2)R mRNA transcript levels are regulated through nuclear factor-kappa-B (NFkappaB) signaling. BAY 11-7085 70-81 nuclear factor kappa B subunit 1 Homo sapiens 200-222 19317852-4 2009 The up-regulation of the P2Y(2)R was abrogated by pre-incubation with Bay 11-7085, an IkappaB-alpha phosphorylation inhibitor, which suggests that P2Y(2)R mRNA transcript levels are regulated through nuclear factor-kappa-B (NFkappaB) signaling. BAY 11-7085 70-81 nuclear factor kappa B subunit 1 Homo sapiens 224-232 17501665-10 2007 NF-kappaB function was studied using BAY 11-7085 and by siRNA transfection to inhibit p65 synthesis. BAY 11-7085 37-48 nuclear factor kappa B subunit 1 Homo sapiens 0-9 19325926-8 2009 Additionally, we find that the NF-kappaB inhibitor BAY 11-7085 synergizes with MS-275. BAY 11-7085 51-62 nuclear factor kappa B subunit 1 Homo sapiens 31-40 18064564-7 2008 Disruption of the NF-kappaB pathway by BAY 11-7085 or IkappaB-SR mimicked the action of MG-132 in promoting HDACi-induced cell death. BAY 11-7085 39-50 nuclear factor kappa B subunit 1 Homo sapiens 18-27 18480072-4 2008 Cotreatment with the NF-kappaB inhibitor, Bay 117085, prevented OHE(2)-induced COX-2 mRNA accumulation, suggesting that OHE(2) induced COX-2 expression via the NF-kappaB dependent pathway. BAY 11-7085 42-52 nuclear factor kappa B subunit 1 Homo sapiens 21-30 18480072-4 2008 Cotreatment with the NF-kappaB inhibitor, Bay 117085, prevented OHE(2)-induced COX-2 mRNA accumulation, suggesting that OHE(2) induced COX-2 expression via the NF-kappaB dependent pathway. BAY 11-7085 42-52 nuclear factor kappa B subunit 1 Homo sapiens 160-169 18583231-3 2008 The effects of cells pretreatment with antioxidant NAC (10 mmol/L) and nuclear factor-kappaB (NF-kappaB) inhibitors BAY 11-7085 (10 micromol/L) and TPCK (10 micromol/L) were also tested on ABCA1 and ABCG1 expressions. BAY 11-7085 116-127 nuclear factor kappa B subunit 1 Homo sapiens 94-103 18515353-6 2008 This quantity of p3NF-luc-3NF dropped dramatically to that of pTAL-luc in the presence of the BAY 11-7085, an inhibitor of NFkappaB activation. BAY 11-7085 94-105 nuclear factor kappa B subunit 1 Homo sapiens 123-131 17636246-5 2007 Inhibition of the NF-kappaB pathway using BAY 11-7085 prevents both CD40 and HLA-DR expression and cytokine production induced by NiSO(4). BAY 11-7085 42-53 nuclear factor kappa B subunit 1 Homo sapiens 18-27 16784892-8 2006 The regulation of YY1 expression and activity by NF-kappaB was demonstrated by the use of the NF-kappaB inhibitor Bay 11-7085 and by the use of a GFP reporter system whereby deletion of the YY1-tandem binding site in the promoter significantly enhanced GFP expression. BAY 11-7085 114-125 nuclear factor kappa B subunit 1 Homo sapiens 49-58 17581194-8 2007 AP-induced CXC chemokine was sensitive to PTX and activation of NF-kappaB was inhibited by BAY11-7085. BAY 11-7085 91-101 nuclear factor kappa B subunit 1 Homo sapiens 64-73 15670752-9 2005 Importantly, TPA-induced TLR2 expression was inhibited by blockage of NF-kappaB activation using NF-kappaB inhibitors, including MG132 and BAY11-7085. BAY 11-7085 139-149 nuclear factor kappa B subunit 1 Homo sapiens 70-79 15525793-3 2005 Cilostazol ( approximately 1-100 microM) concentration dependently repressed these variables as did (E)3-[(4-t-butylphenyl)sulfonyl]-2-propenenitrile (BAY 11-7085) (10 microM), a specific nuclear factor-kappaB (NF-kappaB) inhibitor. BAY 11-7085 151-162 nuclear factor kappa B subunit 1 Homo sapiens 188-209 15525793-3 2005 Cilostazol ( approximately 1-100 microM) concentration dependently repressed these variables as did (E)3-[(4-t-butylphenyl)sulfonyl]-2-propenenitrile (BAY 11-7085) (10 microM), a specific nuclear factor-kappaB (NF-kappaB) inhibitor. BAY 11-7085 151-162 nuclear factor kappa B subunit 1 Homo sapiens 211-220 15342391-11 2004 Addition of genistein and BAY 11-7085 resulted in a decrease in NFkappaB, PIM-2 and defender against cell death 1 as well as a reversal of the inhibition of apoptosis. BAY 11-7085 26-37 nuclear factor kappa B subunit 1 Homo sapiens 64-72 15569997-6 2004 Inhibition of NFkappaB activity by treatment with an IkappaBalpha phosphorylation inhibitor (BAY 11-7085) attenuated both basal and transient induction of IkappaBalpha phosphorylation by paclitaxel. BAY 11-7085 93-104 nuclear factor kappa B subunit 1 Homo sapiens 14-22 15569997-7 2004 Treatment with BAY 11-7085 also enhanced the inhibition of NFkappaB activity by paclitaxel for up to 24 hours. BAY 11-7085 15-26 nuclear factor kappa B subunit 1 Homo sapiens 59-67 15048072-7 2004 Inhibition of NF-kappa B activity by the chemical inhibitor Bay 11-7085, like DETANONOate, sensitized CaP to TRAIL apoptosis. BAY 11-7085 60-71 nuclear factor kappa B subunit 1 Homo sapiens 14-24 15197768-11 2004 A specific inhibitor of NF-kappa B, BAY 11-7085, also blocked the stimulatory effect of BTC. BAY 11-7085 36-47 nuclear factor kappa B subunit 1 Homo sapiens 24-34 15300209-2 2004 We hypothesize that inhibition of NF-kappaB using BAY-11-7085 will sensitize NSCLC cells to death, induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). BAY 11-7085 50-61 nuclear factor kappa B subunit 1 Homo sapiens 34-43 15300209-12 2004 SAHA significantly induced NF-kappaB-dependent transcription which was ameliorated after treatment with BAY-11-7085 (P = .01). BAY 11-7085 104-115 nuclear factor kappa B subunit 1 Homo sapiens 27-36 15026414-6 2004 Inhibition of NFkappaB activity either by treatment with the IkappaBalpha phosphorylation inhibitor (BAY 11-7085) or a specific NFkappaB nuclear translocation inhibitor (SN-50) or by transfection of p50DeltaNLS (which lacks the nuclear localization signal domain) increased the efficacy of both the cisplatin-induced attenuation of IkappaBalpha phosphorylation and NFkappaB activity and the cisplatin-induced apoptosis. BAY 11-7085 101-112 nuclear factor kappa B subunit 1 Homo sapiens 14-22 12857884-8 2003 Finally, treatment of RhoA-transformed cells with Bay11-7083, a specific NF-kappaB inhibitor, leads to inhibition of cell proliferation. BAY 11-7085 50-60 nuclear factor kappa B subunit 1 Homo sapiens 73-82 14872485-10 2004 NF-kappaB inhibitors N-acetyl-L-cysteine and Bay 11-7085 and PI 3-kinase inhibitor LY294002 inhibited the enhancing effects of IL-18, but MAPK p38 inhibitor SB203580, ERK inhibitor PD98059, and JNK inhibitor SP600125 did not. BAY 11-7085 45-56 nuclear factor kappa B subunit 1 Homo sapiens 0-9 11507084-3 2001 Although Bay 11-7085 prevented phorbol 12-myristate 13-acetate-induced NF-kappaB nuclear translocation, SN50, a specific inhibitor of nuclear translocation and function of NF-kappaB, did not induce any significant nuclear/DNA fragmentation, caspase 3 activation, or cell death. BAY 11-7085 9-20 nuclear factor kappa B subunit 1 Homo sapiens 71-80 12480916-7 2002 Both the TNF-alpha antiapoptotic effect and NF-kappaB-DNA binding activity were significantly inhibited by NF-kappaB inhibitors, Bay 11-7085, MG-132, and adenovirus-expressing mutated IkappaB-alpha. BAY 11-7085 129-140 nuclear factor kappa B subunit 1 Homo sapiens 44-53 11703322-6 2001 Inhibition of constitutively active NF-kappa B, by either proteasome inhibitors (MG132, gliotoxin) or inhibitors of I kappa B phosphorylation (Bay117082, and Bay117085), induced apoptosis as demonstrated by both flow cytometric analysis and light microscopic morphological evaluation. BAY 11-7085 158-167 nuclear factor kappa B subunit 1 Homo sapiens 36-46 11507084-7 2001 These data suggest that Bay 11-7085 induces apoptosis through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. BAY 11-7085 24-35 nuclear factor kappa B subunit 1 Homo sapiens 90-99 11428868-6 2001 This induction was completely blocked by simultaneous administration of the two drugs or by incubation with inhibitors for activation of NF-kappaB such as BAY11-7085, CAPE, and parthenolide. BAY 11-7085 155-165 nuclear factor kappa B subunit 1 Homo sapiens 137-146